393 related articles for article (PubMed ID: 16283534)
1. How modeling and simulation have enhanced decision making in new drug development.
Miller R; Ewy W; Corrigan BW; Ouellet D; Hermann D; Kowalski KG; Lockwood P; Koup JR; Donevan S; El-Kattan A; Li CS; Werth JL; Feltner DE; Lalonde RL
J Pharmacokinet Pharmacodyn; 2005 Apr; 32(2):185-97. PubMed ID: 16283534
[TBL] [Abstract][Full Text] [Related]
2. The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain.
Lockwood PA; Cook JA; Ewy WE; Mandema JW
Pharm Res; 2003 Nov; 20(11):1752-9. PubMed ID: 14661918
[TBL] [Abstract][Full Text] [Related]
3. Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.
Lehr T; Staab A; Trommeshauser D; Schaefer HG; Kloft C
AAPS J; 2010 Jun; 12(2):117-29. PubMed ID: 20077053
[TBL] [Abstract][Full Text] [Related]
4. Model-based drug development.
Lalonde RL; Kowalski KG; Hutmacher MM; Ewy W; Nichols DJ; Milligan PA; Corrigan BW; Lockwood PA; Marshall SA; Benincosa LJ; Tensfeldt TG; Parivar K; Amantea M; Glue P; Koide H; Miller R
Clin Pharmacol Ther; 2007 Jul; 82(1):21-32. PubMed ID: 17522597
[TBL] [Abstract][Full Text] [Related]
5. Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease.
Lockwood P; Ewy W; Hermann D; Holford N
Pharm Res; 2006 Sep; 23(9):2050-9. PubMed ID: 16906456
[TBL] [Abstract][Full Text] [Related]
6. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
Gieschke R; Steimer JL
Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
[TBL] [Abstract][Full Text] [Related]
7. Drug research: from the idea to the product.
Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
[TBL] [Abstract][Full Text] [Related]
8. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial.
Gilron I; Bailey JM; Tu D; Holden RR; Jackson AC; Houlden RL
Lancet; 2009 Oct; 374(9697):1252-61. PubMed ID: 19796802
[TBL] [Abstract][Full Text] [Related]
9. The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation.
Nixon RM; O'Hagan A; Oakley J; Madan J; Stevens JW; Bansback N; Brennan A
Pharm Stat; 2009; 8(4):371-89. PubMed ID: 19340851
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.
Chien JY; Friedrich S; Heathman MA; de Alwis DP; Sinha V
AAPS J; 2005 Oct; 7(3):E544-59. PubMed ID: 16353932
[TBL] [Abstract][Full Text] [Related]
11. Optimal decision-making in oncology development programs based on probability of success for phase III utilizing phase II/III data on response and overall survival.
Götte H; Xiong J; Kirchner M; Demirtas H; Kieser M
Pharm Stat; 2020 Nov; 19(6):861-881. PubMed ID: 32662598
[TBL] [Abstract][Full Text] [Related]
12. A framework for joint modeling and joint assessment of efficacy and safety endpoints for probability of success evaluation and optimal dose selection.
He W; Cao X; Xu L
Stat Med; 2012 Feb; 31(5):401-19. PubMed ID: 22161805
[TBL] [Abstract][Full Text] [Related]
13. The need for thorough phase II studies in medicines development for Alzheimer's disease.
Gray JA; Fleet D; Winblad B
Alzheimers Res Ther; 2015 Oct; 7(1):67. PubMed ID: 26503107
[TBL] [Abstract][Full Text] [Related]
14. Dose selection in seamless phase II/III clinical trials based on efficacy and safety.
Kimani PK; Stallard N; Hutton JL
Stat Med; 2009 Mar; 28(6):917-36. PubMed ID: 19152231
[TBL] [Abstract][Full Text] [Related]
15. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
[TBL] [Abstract][Full Text] [Related]
16. Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint.
Huang B; Talukder E; Han L; Kuan PF
J Biopharm Stat; 2019; 29(1):189-202. PubMed ID: 29969380
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia is different from that on neuroma pain in the rat neuropathic pain model.
Miyazaki R; Yamamoto T
Anesth Analg; 2012 Jul; 115(1):182-8. PubMed ID: 22415534
[TBL] [Abstract][Full Text] [Related]
18. Validation of a novel approach for dose individualization in pharmacotherapy using gabapentin in a proof of principles study.
Blau GE; Orcun S; Laínez JM; Reklaitis GV; Suvannasankha A; Fausel C; Anaissie EJ
Pharmacotherapy; 2013 Jul; 33(7):727-35. PubMed ID: 23553679
[TBL] [Abstract][Full Text] [Related]
19. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
Kuhlmann J
Arzneimittelforschung; 2004; 54(5):251-8. PubMed ID: 15212186
[TBL] [Abstract][Full Text] [Related]
20. Time-to-event analysis with treatment arm selection at interim.
Di Scala L; Glimm E
Stat Med; 2011 Nov; 30(26):3067-81. PubMed ID: 21898523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
